Liver support technology - An update

Xenotransplantation

Volumn 13, Issue 5, 2006, Pages 380-389

  Rozga, Jacek ^a  

^a Arbios Systems Inc   (United States)

Author keywords

Acute liver failure; Artificial liver; Bioartificial liver; Blood detoxification; Blood therapy

Indexed keywords

ALBUMIN DIALYSIS; BIOARTIFICIAL LIVER; BIOSYNTHESIS; BIOTRANSFORMATION; CHRONIC LIVER DISEASE; DETOXIFICATION; HEMODIAFILTRATION; LIVER CELL; LIVER FAILURE; LIVER FUNCTION; LIVER SUPPORT; MEDLINE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ANIMALS; HEMODIAFILTRATION; HEPATOCYTES; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; RENAL DIALYSIS; SORPTION DETOXIFICATION; SWINE;

EID: 33747625427     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/j.1399-3089.2006.00323.x     Document Type: Review

References (67)

1. National Vital Statistics Report, vol. 52, no. 9; Table D. 2003, p. 8.
2. DIETREICH D. Strategies for the management of HCV/HIV coinfection. In: Hepatitis C. Disease Management Guide. 3rd edn. PDR, 2005: 101-113.
3. CDC. Centers for Disease Control and Prevention - National Center for Infectious Diseases. http://www.cdc.gov/ncidod/diseases/hepatitis/resources/ dz_burden02.htm.
4. DAVIS GL, ALBRIGHT JE, COOK SF, ROSENBERG DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331.
5. SCHIODT FV, ATILLASOY E, SHAKIL AO et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 1999; 5: 86.
6. TREY C, DAVIDSON C. The management of fulminant hepatic failure. Progr Liver Dis 1970; 3: 282.
7. BERNAU J, RUEFF B, BENHAMOU J-P. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986; 6: 97.
8. ASCHER NL, LAKE JR, EMOND JC et al. Liver transplantation for fulminant hepatic failure. Arch Surg 1993; 128: 677.
9. LEE WM. Acute liver failure. N Engl J Med 1993; 329: 1862.
10. FARGES O, KALIL N, SAMUEL D et al. The use of ABO-incompatible grafts in liver transplantation; a life-saving procedure in highly selected patients. Transplantation 1995; 59: 1124.
11. ROZGA J, SUH KS, LILIJA H, ARNAOUT W, DEMETRIOU AA. Liver support system development. In: DEMETRIOU AA, ed. Support of the Acutely Failing Liver, 2nd edn. Georgetown, TX, USA: R.G. Landes Co., 2000.
12. ROZGA J. Extracorporeal support of the failing liver. Med Sci Monitor 2001; 7 (Suppl. 1): 78.
13. ALLEN JW, HASSANEIN T, BHATIA SN. Advances in bioartificial liver devices. Hepatology 2001; 34: 447.
14. VAN DE KERKHOVE MP, HOEKSTRA R, CHAMULEAU AFM, VAN GULIK TM. Clinical application of bioartificial liver support systems. Ann Surg 2004; 240: 216.
15. KILEY JE, WELCH HF, PENDER JC. Removal of blood ammonia by hemodialysis. Proc Soc Exp Biol Med 1956; 91: 489.
16. SABIN S, MERRITT JA. Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange). Ann Intern Med 1968; 68: 1.
17. LEPORE MJ, STUTMAN LJ, BONANNO C et al. Plasmapheresis with plasma exchange in hepatic coma. Arch Intern Med 1972; 129: 900.
18. DENIS J, OPOLON P, NUSINOVICI V et al. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut 1978; 19: 787.
19. GIMSON AES, MELLON PJ, BRAUDE S et al. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; 2: 681.
20. ZIEVE L. Metabolic abnormalities in hepatic coma and potential toxins to be removed. In: WILLIAMS R, MURRAY-LYON IM, eds. Artificial Liver Support. London: Pitman, 1975.
21. KONDRUP J, ALMDAL T, VILSTRUP H, TYGSTRUP N. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 1992; 15: 669.
22. HIROKO I, MASAHITO N, TOMOO N. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998; 26: 873.
23. MUNOZ SJ, BALLAS SK, MORITZ MJ et al. Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis. Transplant Proc 1989; 21: 3535.
24. YOSHIBA M, INOUE N, SANJO T et al. Plasmapheresis in acute liver failure. In: NOSE Y, MALCHESKY PS, SMITH JW, KRAKAUER RS, eds. Plasmapheresis Therapeutic Applications and New Techniques. New York: Raven Press, 1983.
25. BRUNNER G, LOSGEN H. Benefits and dangers of plasma exchange in patients with fulminant hepatic failure. In: ODA T, SHIOKAWA Y, INOUE N, eds. Therapeutic Plasmapheresis, VI Therapeutic Plasmapheresis, VI. Cleveland, OH: ISAO Press, 1987.
26. DE SILVESTRO G, MARSON P, BRANDOLESE R, PITTONI G, ONGARO G. A single institution's experience with plasma-exchange therapy in patients with fulminant hepatic failure. Int H Artif Organs (1982-1999) 2000: 454.
27. STANGE J, RAMLOW W, MITZNER S, SCHMIDT R, KLINKMANN H. Dialysis against a recycled albumin solution enables the removal of albumin bound toxins. Artif Organs 1993; 17: 809.
28. STANGE J, MITZNER SR, RISLER T et al. Molecular Adsorbent Recycling System (MARS): clinical results of a new membrane based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319.
29. JALAN R, SEN S, STEINER C. The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. Liver Transplant 2005; 7: 853.
30. STROBL W, KRAMER L, VOGT G et al. The fractionated plasma separation and adsorption system; in vitro evaluation and first clinical results. ASAIO J 1999; 45: 194.
31. RIFAI K, ERNST Y, KRETSCHMER U et al. Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984.
32. KREYMANN B, SEIGE M, SCHWEIGART U, KOPP KF, CLASSEN M. Albumin dialysis: effective removal of copper in a patient with fulminant Wilson disease and successful bridging to liver transplantation: a new possibility for the elimination of protein-bound toxins. J Hepatol 1999; 31: 1080.
33. PESZYNSKI P, KLAMMT S, PETERS E et al. Albumin dialysis: single pass vs. recirculation (MARS). Liver 2002; 22 (Suppl.): 40.
34. SAUER IM, GOETZ M, STEFFEN I et al. In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 2004; 39: 1408.
35. EGUCHI S, KAMLOT A, LJUBIMOVA J et al. Fulminant hepatic failure in rats: survival and effects on blood chemistry and liver regeneration. Hepatology 1996; 24: 1452.
36. EGUCHI S, LILJA MH, KAMLOT A et al. Loss and recovery of liver regeneration in rats with fulminant hepatic failure. J Surg Res 1997; 72: 112.
37. SUK KS, LILJA H, KAMOHARA Y et al. Bioartificial liver treatment in fulminant hepatic failure rats: effect on DNA binding activity of growth-induced and liver-enriched transcription factors. J Surg Res 1999; 85: 243.
38. TSUBOUCHI H, HIRONO S, GOHDA E et al. Clinical significance of human hepatocyte growth factor in blood from patients with fulminant hepatic failure. Hepatology 1989; 9: 875.
39. ROZGA J, UMEHARA Y, TROFIMENKO A, SADAHIRO T, DEMETRIOU AA. A novel plasma filtration therapy for hepatic failure: preclinical studies. Ther Apher Dialysis 2005; 10: 138.
40. SORRENTINO F. Prime ricerche per la realizzatione di un fegato artificiale. Chirurgia Patologica Sperimentale 1956; 4: 1401.
41. WOLF CFW, MUNKELT BE. Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries. ASAIO Trans 1975; 21: 16.
42. ROZGA J, HOLZMAN MD, RO M-S et al. Hybrid bioartificial liver support treatment of animals with severe ischemic liver failure. Ann Surg 1993; 217: 502.
43. BRUNNER G, HOLLOWAY CJ, LOSGEN H. The application of immobilized enzymes in an artificial liver support system. Artif Organs 1979; 3: 27.
44. DENTI E, LUBOZ MP. Preparation and properties of gel-entrapped liver cell microsomes. In: WILLIAMS R, MURRAY-LYON IM, eds. Artificial Liver Support. Kent, UK: Pitman Medical, 1974.
45. KIMURA K, GUNDERMANN KJ, LIE TS. Hemoperfusion over small liver pieces for liver support. Artif Organs 1980; 4: 297.
46. SUSSMAN NL, CHONG MG, KOUSSAYIR T et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16: 60.
47. FREMOND B, MALANDAIN C, GUYOMARD C et al. Correction of bilirubin conjugation in the Gunn rat using hepatocytes immobilized in alginate beads as an extra-corporeal bioartificial liver. Cell Transplant 1993; 2: 453.
48. FLENDRIG LM, LA SOE JW, JORNING GG et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound non-woven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997; 26: 1379.
49. GERLACH J, TROST T, RYAN CJ et al. Hybrid liver support system in a short term application in hepatectomized pigs. Int J Artif Organs 1994; 17: 549.
50. YANAGI K, MIYOSHI H, OSHIMA N. Improvement of metabolic performance of hepatocytes cultured in vitro in a packed-bed reactor for use as a bioartificial liver. ASAIO J 1998; 44: M436.
51. NARUSE K, NAGASHIMA I, SAKAI Y et al. Efficacy of a bioreactor filled with porcine hepatocytes immobilized on non-woven fabric for ex vivo direct hemoperfusion treatment of liver failure in pigs. Artif Organs 1998; 22: 1031.
52. NAKAZAWA K, IJIMA H, KANEKO M et al. Development of a hybrid artificial liver support system and its application to hepatic failure animals. In: IKADA Y, OKANO T, eds. Tissue Engineering for Therapeutic Use 3. Amsterdam: Elseviere Science B.V., 1999.
53. ELLIS AJ, HUGHES RD, WENDON JA et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446.
54. MUNDT A, PUHL G, MULLER A et al. A method to assess biochemical activity of liver cells during clinical application of extracorporeal hybrid liver support. Int J Artif Organs 2002; 25: 542.
55. SAUER IM, ZEILINGER K, OBERMAYER N et al. Primary human liver cells as source of modular extracorporeal liver support - a preliminary report. Int J Artif Organs 2002; 25: 1001.
56. PATIENCE C, TAKEUCHI Y, WEISS RA. Infection of human cells by an endogenous retrovirus of pigs. Nat Med 1997; 3: 282.
57. PARADIS K, LANGFORD G, LONG Z et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 1999; 285: 1236.
58. PITKIN Z, MULLON C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999; 23: 829.
59. VAN DE KERKHOVE MP, DI FLORIO S, SCUDERI V et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs 2002; 25: 950.
60. ROZGA J, WILLIAMS RF, MOSCIONI AD et al. Development of a bioartificial liver support system. Hepatology 1993; 17: 258.
61. ROZGA J, PODESTA L, LEPAGE E et al. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet 1993; 342: 898.
62. WATANABE FD, MULLON CJP, HEWITT WR et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997; 225: 484.
63. DEMETRIOU AA, BROWN RS, BUSUTTIL RW et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660.
64. XUE YL, ZHAO SF, LUO Y et al. TECA hybrid artificial liver support system in treatment of acute liver failure. World J Gastroenterol 2001; 7: 706.
65. DING YT, QIU YD, CHEN Z et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients. World J Gastroenterol 2003; 9: 829.
66. Mazariegos GV, Kramer DJ, Lopez RC et al. Safety observations in phase I clinical evaluation of the excorp medical bioartificial liver support system after the first four patients. ASAIO J 2001; 25: 471.
67. MORSIANI E, PAZZI P, PUVIANI AC et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs 2002; 25: 192.